Pharmaprojects

Antidiabetic glitazar market uncertain after five companies cease development, report finds

Published in Medicine and Law Weekly, October 13th, 2006

Pharmaprojects, a database tracker of pharmaceutical R&D companies, notes that the recent discontinuation by Takeda of its predicted blockbuster antidiabetic drug sipoglitazar (TAK-654), due to insufficient safety and efficacy, brings the number of glitazar antidiabetics that have failed in clinical trials to five.

Pharmaprojects reports just three glitazars still in ongoing clinical trials, calling into question the validity of this class of drug for the treatment of diabetes. Furthermore, an examination of Pharmaprojects' extensive data for drugs acting on the same molecular targets indicates a similar trend, with seven discontinuations, one project suspension and no...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly

Source: Medicine and Law Weekly (2006-10-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry